Abstract:OBJECTIVE:To explore the best treatment plan of intravesical instillation for patients with non-muscular invasive bladder cancer (NMIBC), to explore recurrence-related clinicopathological factors after intravesical instillation, and to evaluate the value of the prognosis and prediction models currently used for NMIBC patients.METHODS:Starting from 2016, patients who underwent transurethral resection of bladder tumor (TURBT) in our hospital and who received post-surgery diagnosis of having intermediate or high risks for NMIBC were enrolled in the study. They were randomly assigned to different group sat a ratio of 2∶2∶1 for receiving intravesical instillation therapy of Bacillus Calmette-Guérin (BCG) for 19 times, BCG for 15 times, and epirubicin (EPI) for 18 times. The clinicopathological data of the patients were recorded before, during and after instillation therapy, and survival curves were drawn to evaluate the effects of the three regimens, using recurrence-free survival as the endpoint. Clinicopathological data were analyzed to study the associations between various factors and post-instillation recurrence. The consistency index (c-index) was used to evaluate the predictive accuracy of the scoring model of the Spanish Urological Club for Oncological Treatment (CUETO) and the risk tables of European Organization for Research and Treatment of Cancer (EORTC).RESULTS:A total of 93 NMIBC patients (35 in the 19-time BCG group, 37 in the 15-time BCG group, and 21 in the EPI group) were included, with a median follow-up time of 33.46 months. Twenty-two patients experienced tumor recurrence and eight, tumor progression. The survival curve showed that the BCG group had better recurrence-free survival than the EPI group ( P=0.002), while the difference in recurrence-free survival between 19-time BCG and 15-time BCG groups was not statistically significant. Higher general complication rate was seen in the BCG groups compared with the EPI group (84.7% vs. 61.9%, P=0.022), but there was no grade 3-5 adverse events in any group. The c-index of CUETO scoring model and EORTC risk tables was higher than that of the prediction based solely on T stage, nuclear grade, or EAU risk stratification. In addition, the c-index in the BCG group was higher than that in the whole cohort.CONCLUSION:Among the subjects of this study, the recurrence rate of bladder cancer in the intravesical BCG instillation groups was lower than that of the epirubicin group. EORTC risk tables and CUETO scoring model exhibited higher predictive accuracies in BCG-treated patients than its performance for the whole NMIBC cohort.

Validation and analysis of the prognostic value of the EORTC risk tables in chinese patients with nonmuscle invasive bladder cancer treated by immediate postoperative intravesical instillation of chemotherapy

Clinical evaluation of European Organization for Research and Treatment of Cancer risk tables in non-muscle invasive bladder cancer

Are EORTC Risk Tables Suitable for Chinese Patients with Non-Muscle-invasive Bladder Cancer?

EORTC risk tables are more suitable for Chinese patients with nonmuscle-invasive bladder cancer than AUA risk stratification

The Efficacy of the EORTC Risk Table for the Prediction of Recurrence and Progression of Non-Muscle-invasive Bladder Cancer:Report of 248 Cases

Single-dose Instillations of Epirubicin As Prophylaxis for Recurrence of Superficial Bladder Tumors:A Prospective Randomized Controlled Study

Predicting Recurrence and Progression in Chinese Patients with Nonmuscle-Invasive Bladder Cancer Using EORTC and CUETO Scoring Models.

Efficacy of European Organization for Research and Treatment of Cancer ( EORTC ) Risk Tables for the Prediction of Recurrence and Progression of Non-Muscle Invasive Bladder Cancer after Intravesical Pirarubicin Instillation

The evaluation of the risk factors for non-muscle invasive bladder cancer (NMIBC) recurrence after transurethral resection (TURBt) in Chinese population.

Clinical Evaluation of Patients with Mixed Low-and-High Grade Non-muscle Invasive Bladder Cancer with EORTC Risk Scores

Predicting Recurrence and Progression in Non-Muscle-invasive Bladder Cancer after Transurethral Resection Using European Organization of Research and Treatment of Cancer(EORTC) Scoring System

Feasibility Study on Predicting Recurrence Risk of Bladder Cancer Based on Radiomics Features of Multiphase CT Images

A Randomized Controlled Study of Intravesical Instillation Therapy of Bacillus Calmette-Guérin Vs. Epirubicinin Treating Non-muscular Invasive Bladder Cancer

Analysis of risk factors of clinical efficacy of TURBT combined with internal iliac arterial infusion chemotherapy in treatment of NMIBC

Efficacy of Immediate Postoperative Instillation of Chemotherapy for Primary Non-Muscle-Invasive Bladder Cancer in Real-World Clinical Practice

Evaluation of the effects of intra-arterial chemotherapy combined with intravesical chemotherapy against intravesical chemotherapy alone after transurethral resection of bladder tumor in T1-staged Grade 3 bladder cancer

Exploring the risk factors of recurrence and progression in 188 patients with non-muscle invasive bladder cancer by retrospectively analysis

Development of a dynamic risk system for predicting the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer after thulium laser resection of bladder tumor or transurethral resection of bladder tumor followed by intravesical BCG instillation

Effects of Intravenous Chemotherapy after TURBT for High-Risk Nonmuscle Invasive Bladder Cancer: Results of a Retrospective Study

Risk-Based Assessment Of the Impact Of Intravesical Therapy on Recurrence-Free Survival Rate Following Resection of Suspected Low-grade, Non-muscle-invasive Bladder Cancer (NMIBC): A Southwest Oncology Groups (SWOG) S0337 Posthoc Analysis

Comparative efficacy of Bacillus Calmette–Guérin instillation and radical cystectomy treatments for high-risk non-muscle-invasive urothelial cancer classified as high-grade T1 in initial and repeat transurethral resection of bladder tumor